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OBJECTIVE: Restless legs syndrome (RLS) is a neurological dis-
order characterised by unpleasant sensations in the legs and an
irresistible urge to move the legs to relieve the discomfort. This
study aims to describe the drug treatment patterns amongst UK
RLS patients during a 12-month period; in this period pharma-
cological therapy was based on “off-label” use of medication.
METHODS: A data base capturing nationally representative
prescribing for patients presenting in general practice (DIN-
LINK) was used to describe treatments received by patients with
a diagnosis of RLS presenting to a GP in the 12 months up to
31st March 2005 (n = 556). This data base covers a population
of about 800,000 patients and about 400 GPs. RESULTS: Annu-
ally, the number of patients with RLS for which they were receiv-
ing drug treatment was estimated to be up to 46 per 100,000
catchment population (up to 66% of the 70 per 100,000 patients
with RLS who annually make contact with a GP). Drug treat-
ments included the following (the percentages of patients receiv-
ing the different types of drug treatments are shown in brackets):
antidepressants (20% of whom 71% received amitriptyline),
anticonvulsants (18% of whom 76% received clonazepam),
quinine (13%), non-narcotic analgesia (13%), dopamine ago-
nists (5%), hypnotics (6%), tranquilisers (4%) NSAIDs (3%)
and L-dopa (4%). CONCLUSIONS: The substantial percentage
of patients receiving some form of analgesia or treatment for
insomnia may be a reﬂection of the limited success of existing
patterns of treatment in controlling symptoms (presumably, clon-
azepam in line with UK guidelines, was used mostly for insom-
nia). A large proportion of RLS patients were given amitriptyline
which can worsen RLS and quinine, a treatment effective only
when cramps co-exist.
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IMPLANTABLE SYSTEMS PERFORMANCE REGISTRY (ISPR) A
MEDICAL DEVICE AND PATIENT REGISTRY
Stoker V,Weaver T, Hargens L
Medtronic, Minneapolis, MN, USA
OBJECTIVES: ISPR is a prospective, post-market, surveillance
registry designed to monitor implantable neurological devices.
For each patient enrolled demographics, implant and practice
techniques, and patient reported outcomes are collected and ana-
lyzed to elucidate the etiology of device complications. The goal
is to expand registry centers, based on pre-deﬁned criteria, and
generate data representative of the medical community and its
patients. This registry is a foundation and electronic platform for
outcome registry projects. METHODS: Single and multi-physi-
cian centers follow standard clinical practice and a common reg-
istry protocol. Center activation includes software and protocol
training and IRB approval at each center. Information registered
with the U.S Food and Drug and Administration (FDA) man-
dated Device Registration System (DRS) pre-populates the reg-
istry avoiding redundant data submission, while centers provide
additional information through electronic data capture. Active
surveillance occurs at 6-month intervals with data reporting
required for device or patient events. These event data are elec-
tronically communicated to fulﬁll FDA-mandated event report-
ing regulations, thus creating efﬁciencies for the sponsor and
physician. The potential of selection bias in ISPR is minimized
through 100% eligibility of all implanted devices at each center.
The approach for ISPR center expansion is based on geographic,
specialty, and practice distribution to achieve a representative
sampling of real world experience, effectiveness and safety. A
multidisciplinary advisory board oversees reporting with the goal
of peer reviewed scientiﬁc presentation and publication.
RESULTS: Annual aggregate and center speciﬁc reports are gen-
erated including descriptive statistics and survival curves. CON-
CLSUIONS: The data collected in this registry are representative
of the medical community with generalizability to a broader
patient population. ISPR results may illuminate methods to
improve therapy and guide development, provide insight into the
etiology of events through evaluation beyond what is possible
with passive surveillance, and generate best practices associated
with reduced events and improved outcomes.
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USE OF THE SELF-ADMINISTERED NEUROPATHY TOTAL
SYMPTOM SCORE—6 (NTSS-6 SA) IN AN INTERNATIONAL
STUDY
Mear I1, Grataloup G1, Nadjar A1, Seignobos E2,Trudeau E2,
Bastyr E3
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OBJECTIVES: To measure frequency and intensity of diabetic
peripheral neuropathy (DPN) symptoms a 6 item scale was
developed in US English for health care professionals (HCP): the
Neuropathy Total Symptom Score-6 (NTSS-6). Prior to use in an
international study a self-administered (SA) version was devel-
oped and translated into 9 languages. METHODS: The devel-
opment of the SA version involved the establishment of patient
instructions and the comprehension test on 5 US patients with
DPN and 2 diabetologists. The following translation process was
conducted by a specialist in each target country: (1) two forward
translations; (2) back translation; (3) review by a clinician; (4)
comprehension test on 5 subjects with DPN and (5) international
harmonisation. Where translations of the HCP version existed,
an SA version was developed and the accuracy of the transla-
tions checked. RESULTS: The ﬁrst challenge was maintaining
conceptual equivalence between the HCP and SA versions. The
development of the SA version required patients’ understanding
the meaning of the explored symptoms and their level of sever-
ity without clariﬁcation by HCPs. The second challenge was
ﬁnding conceptually equivalent and culturally relevant expres-
sions of the different types of pain. In some instances literal
equivalents for the original symptom existed, but according to
patients did not correspond to the original concept. In other
cases the original did not have a literal equivalent and had to be
paraphrased. CONCLUSIONS: The 9 languages of the NTSS-6
SA were established according to a rigorous development and
translation process to ensure conceptual equivalence and cultural
relevance across languages and ultimately the international com-
parison and pooling of data. Issues encountered during this
process support the advantage of integrating international feed-
back on concepts and wording before ﬁnalizing a scale.
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TREATMENT CHARACTERISTICS
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Different surgical procedures are described to improve hand-
function in tetraplegie either with or without implantation of an
8-channel electrical stimulator. Clinical experience shows that
patients are not always willing to accept these devices despite
their severe functional limitations. This can be explained because
the offered treatment is too demanding. For future clinical appli-
cations and for further technical developments it is necessary to
obtain more insight into the factors that determine willingness
to accept assistive technology. OBJECTIVES: To determine the
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effect of treatment characteristics of upper extremity interven-
tions on the decision of tetraplegic subjects to accept treatment.
METHOD: A discrete choice experiment (DCE) was performed,
where treatment characteristics were obtained to establish dif-
ferent treatment scenarios. Seven different treatment character-
istics were obtained from a panel of international experts.
Tetraplegics were offered 20 sets of two different treatment 
scenarios and asked to select the best scenario. RESULTS: A 
total of 47 tetraplegic subjects with C5–6 lesions, motor group
M1–4 were selected. Relative importance of treatment charac-
teristics were: intervention type (surgery or surgery with FES
implant) 13%, number of operations 15%, in patient rehabili-
tation period 22%, ambulant rehabilitation period 9%, compli-
cation rate 15%, improvement of elbow function 10%,
improvement of hand function 15%. Effects of various changes
of treatment protocols were determined. An inpatient rehabili-
tation period of maximum 4 weeks increases preference for
treatment with 32%. One instead of two operative procedures
increases the preference with 25%. CONCLUSION: In-patient
rehabilitation period appears to have the greatest impact on the
decision by patients to have surgery or not. Implantation of a
neural implant is not the main reason for not accepting this type
of treatment.
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THE ECONOMIC BURDEN OF PARKINSONISM IN ITALY
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OBJECTIVES: The primary objective is to evaluate health, non-
health cost and utilities differences between Parkinson patients
with diagnosis performed through SPECT (Single Proton Emis-
sion Computerized Tomography) and patients diagnosed tradi-
tionally. METHODS: This economic analysis is part of the
prospective, multicentre, observational study DIAPASON (Diag-
nosis of Parkinson’s Disease: Economics and Outcomes Impact),
which involved 17 neurology centers. The present poster presents
the preliminary economic results. Inclusion criteria: all subjects
with suspect parkinsonism, “de novo” patients or in dopamin-
ergic therapy for 3 months at the most. Exclusion criteria: subject
with dementia senile, subjects treated with antidopaminergic
drugs, subjects with iatrogenic forms of disease already known
or clear vascular lesions of substantia nigra or caudato or
putamen. The prospectives used in the study were: national
health system (NHS) and society. Data were collected using an
electronic case report form. Utilities were calculated using the
EuroQol (EQ-5D) questionnaire. RESULTS: In November 2004,
147 patients (50 NO SPECT, 97 SPECT) had already performed
the second visit. For both ﬁrst and second visit the total cost for
patients with diagnosis performed through SPECT was higher
than that obtained for patients diagnosed traditionally: the mean
health cost supported by NHS per patient was €2,577.79
(€1,562.63 for NO SPECT patients and €3,024.00 for SPECT
ones), and mean non health cost obtained per patient was
€3,553.56 (€3923.44 for SPECT patients, €2712.08 for NO
SPECT patients). For subjects diagnosed traditionally the cost
per QALYs gained was €36,225.2 compared to €15,291.6 for
SPECT patients group. CONCLUSION: The introduction of
new technologies, as SPECT, and the use of new radiolabelled
drugs concur to improve early diagnosis of Parkinson’s disease
and related diseases. Diagnosis using SPECT has health and non
health cost higher than traditional diagnosis, but a cost-utility
analysis demonstrate its cost saving role in comparison with tra-
ditional diagnosis.
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A COST-UTILITY MODEL COMPARING AZILECT®
(RASAGILINE) WITH STANDARD CARE AND ENTACAPONE IN
THE TREATMENT OF PARKINSONIAN PATIENTS WITH
MOTOR FLUCTUATIONS UNDER LEVODOPA IN FINLAND
Hudry J1, Rinne J2, Keränen T3, Eckert L1, Cochran J1, François C1
1H. Lundbeck A/S, Paris, France; 2University of Turku,Turku, Finland;
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OBJECTIVE: Assess the cost-utility of rasagiline, entacapone
and standard care (levodopa) in Parkinson’s disease (PD) patients
with motor ﬂuctuations in Finland. METHODS: A 2-year prob-
abilistic Markov model with 3 health states: £25% off-time/day’,
‘>25% off-time/day’ and ‘dead’ was used. Model inputs included
transition probabilities from randomised clinical trials, utilities
from a preference measurement study and costs and resources
from a Finnish cost-of-illness study. Effectiveness measures were
Quality Adjusted Life Years (QALYs) and number of months
spent with £25% off-time/day. The primary analysis was per-
formed from the societal perspective. Extensive sensitivity and
subgroup analyses on severe patients were performed. A parity
price was assumed for rasagiline and entacapone based on
WHO-DDD. RESULTS: Over 2 years, rasagiline appeared to
show both greater effectiveness and cost reductions compared
with standard care (0.38 additional QALYs, over 55% addi-
tional time spent with £25% off-time/day and €900 savings
(95% CI: [-€3400; €1090]) per treated patient. Rasagiline and
entacapone yielded similar effectiveness and costs. A trend in
favour of rasagiline was observed in the severe patient subgroup
(approximately €660 total cost savings/patient). Sensitivity
analyses conﬁrmed robustness of the results vs. standard care.
Results vs. entacapone were sensitive to changes in transition
probabilities and drug prices. CONCLUSION: This economic
model supports the use of rasagiline as a cost-effective treatment
compared with levodopa alone and combined with entacapone
in PD patients with motor ﬂuctuations in Finland. Further
improvements of the model should be applied to different set-
tings to conﬁrm these results.
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COST-EFFECTIVENESS OF CONTINUOUS DUODENAL
DELIVERY OF LEVODOPA (DUODOPA®) IN PATIENTS WITH
SEVERE PARKINSON’S DISEASE
Kristiansen IS1, Bingefors K2, Isacson D2
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OBJECTIVE: To explore costs and health beneﬁts of replacing
conventional oral therapy with intraduodenal infusion of car-
bidopa/levodopa (Duodopa®) for severe Parkinson’s disease
(PD). METHODS: In the DIREQT trial 24 patients aged 50–79
years with Hoehn & Yahr stage 2.5–4.0 (at best) were ran-
domised to receive either three weeks of conventional oral
therapy followed by three weeks of Duodopa, or vice versa.
Later, patients could choose to switch permanently to Duodopa.
Health Related Quality of Life (HRQOL) was recorded with the
15D instrument at entry into the trial, during the trial, and then
at 8 follow-ups during the subsequent 6 months. Use of health
care was registered before, during and after the trial. Two-year
costs and health consequences of Duodopa and conventional
therapy were estimated in a decision analytic model. Costs were
based on market prices and customary charges in Sweden.
RESULTS: The mean quality-of-life scores were 0.77 for
Duodopa and 0.72 for conventional therapy with considerable
variation in scores for individual patients over time. The
expected two year cost was $93,600 for Duodopa and $28,700
for conventional oral therapy. The expected number of Quality
